Department of Population Health Sciences, School of Life Course and Population Sciences, King's College London, London, United Kingdom.
National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
Neuroepidemiology. 2022;56(4):240-249. doi: 10.1159/000525672. Epub 2022 Jun 26.
Statins are effective in preventing vascular disease and are widely recommended and used for the secondary prevention of ischemic stroke. However, there is concern from trials that statins might increase the risk of hemorrhagic stroke, partially reducing their benefit. We sought to systematically review the latest evidence on this question.
Four electronic databases were searched to identify published randomized controlled trials (RCTs) and observational cohort studies (search date December 2020). Two independent reviewers carried out the eligibility assessment based on predefined inclusion criteria. We examined the outcomes of recurrent stroke (after ischemic stroke) of any type, and separately recurrent ischemic stroke and recurrent hemorrhagic stroke. RCTs and observational cohort studies were meta-analyzed separately. Odds ratios (ORs) were used to assess the effect of statin therapy. Meta-analysis was conducted using RevMan 5.4 software.
We retrieved 559 papers in searches, of which 11 RCTs and 12 observational cohort studies were included. Both RCTs and observational studies found that statins reduced the odds of stroke of any type in those with an initial ischemic stroke (11 RCTs: OR = 0.87, 95% CI [0.77,0.97]; p = 0.02; 12 cohort studies: OR = 0.80, 95% CI [0.66, 0.96]; p = 0.02). Both RCTs and observational studies found that recurrence of ischemic stroke was reduced by statins (6 RCTs: OR = 0.81, 95% CI [0.70, 0.93]; p = 0.002; 3 observational studies: OR = 0.67, 95% CI [0.61, 0.75]; p < 0.00001). Data from 7 RCTs and 8 cohort studies did not find a significant difference in hemorrhagic stroke but could not rule out a substantial increase or reduction (7 RCTs: OR = 1.15, 95% CI [0.62, 2.13]; p = 0.66; 8 cohort studies: OR = 0.93, 95% CI [0.71, 1.21]; p = 0.59).
In people who have experienced an ischemic stroke, statins reduce the risk of recurrent stroke of any type medicated through a reduction of ischemic stroke. We found no increase in the risk of hemorrhagic stroke.
他汀类药物在预防血管疾病方面具有显著效果,被广泛推荐用于缺血性中风的二级预防。然而,临床试验的结果显示他汀类药物可能会增加出血性中风的风险,从而部分降低其益处。因此,我们旨在系统性地回顾这方面的最新证据。
我们检索了四个电子数据库,以确定已发表的随机对照试验(RCT)和观察性队列研究(检索日期为 2020 年 12 月)。两名独立的评审员根据预设的纳入标准进行了资格评估。我们评估了任何类型的复发性中风(继缺血性中风之后)的结局,以及复发性缺血性中风和复发性出血性中风的结局。分别对 RCT 和观察性队列研究进行了荟萃分析。使用比值比(OR)评估了他汀类药物治疗的效果。使用 RevMan 5.4 软件进行了荟萃分析。
我们在搜索中检索到 559 篇论文,其中纳入了 11 项 RCT 和 12 项观察性队列研究。RCT 和观察性研究均发现,在经历初始缺血性中风的患者中,他汀类药物降低了任何类型中风的发生风险(11 项 RCT:OR = 0.87,95%CI [0.77,0.97];p = 0.02;12 项队列研究:OR = 0.80,95%CI [0.66,0.96];p = 0.02)。RCT 和观察性研究均发现,他汀类药物降低了复发性缺血性中风的发生风险(6 项 RCT:OR = 0.81,95%CI [0.70,0.93];p = 0.002;3 项观察性研究:OR = 0.67,95%CI [0.61,0.75];p < 0.00001)。来自 7 项 RCT 和 8 项队列研究的数据未发现出血性中风的发生率有显著差异,但不能排除增加或减少的可能性(7 项 RCT:OR = 1.15,95%CI [0.62,2.13];p = 0.66;8 项队列研究:OR = 0.93,95%CI [0.71,1.21];p = 0.59)。
在经历过缺血性中风的患者中,他汀类药物通过降低缺血性中风的发生率来降低任何类型复发性中风的风险。我们没有发现出血性中风风险增加。